XWEL vs CDNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 18, 2026

XWEL

38.4
AI Score
VS
XWEL Wins

CDNA

31.0
AI Score

Investment Advisor Scores

XWEL

38score
Recommendation
SELL

CDNA

31score
Recommendation
EXTENDED

AI Analyst Insights

Detailed Metrics Comparison

Metric XWEL CDNA Winner
Forward P/E 10.7875 151.5152 XWEL
PEG Ratio 0 -0.12 Tie
Revenue Growth -7.1% 52.2% CDNA
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 38.4/100 31.0/100 XWEL
Profit Margin -82.9% 24.2% CDNA
Beta 1.00 1.00 Tie
AI Recommendation SELL EXTENDED CDNA

Relative Price Performance (Last 90 Days)

XWEL 1M: -13.3% · 3M: -23.1% CDNA 1M: +35.4% · 3M: +131.1%

Current Technical Phase

XWEL

Markdown
Sell / avoid

Price below a falling SMA50 (slope -5.0%), weak momentum, RSI 35

RSI (14): 35.4 · Price: $0.84

CDNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (24.8% over 20 days), RSI 81

RSI (14): 81.3 · Price: $67.15

Fundamentals Snapshot

Metric XWEL CDNA
Market Cap — —
Forward P/E 10.8 52.1
Trailing P/E — 31.8
Revenue (TTM) — —
Revenue Growth -0.1% 0.5%
Gross Margin 0.3% 0.7%
Operating Margin -0.3% 0.0%
EPS -5.21 2.08
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, XWEL is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.